Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-SWITCH: Berobenatide for Weight Maintenance in Adults on Semaglutide or Tirzepatide
NCT07845500Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 3 trial of berobenatide in obesity, sponsored by Pfizer. Started Sep 2026; status: recruiting.
02
Drugs
berobenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07845500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845500.